Validating the pathogenicity of EIF2AK4 variants is therefore of significant diagnostic value, which is important since therapies developed for classical PAH can be detrimental in these rare subtypes [7]. This evidence concerns the gene EIF2AK4 and pulmonary arterial hypertension.